Avalo Therapeutics (AVTX) Shares Outstanding (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Shares Outstanding (Entity) data on file, last reported at $20.1 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 85.7% year-over-year to $20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.1 million (up 85.7% YoY) and the FY2025 annual result came in at $13.4 million, up 202.86% from the prior year.
• Shares Outstanding (Entity) grew to $20.1 million in Q1 2026, from $13.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $20.1 million in Q1 2026 to a low of $1.0 in Q3 2022.
• A 5-year average of $4.8 million and a median of $859381.0 in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) plunged 100.0% — and 2023, when it soared 19500500.0%.
• Tracing AVTX's Shares Outstanding (Entity) over 5 years: stood at $39325.0 in 2022, then surged by 606.24% to $277727.0 in 2023, then jumped by 1493.7% to $4.4 million in 2024, then surged by 202.86% to $13.4 million in 2025, then soared by 50.0% to $20.1 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $20.1 million (Q1 2026), $13.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.